SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-08-28
Accession Number: 0001213900-24-073419
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390024073419/ea020832406ex1-1_synergy.htm

Chunk 13 of 15
Word Count: 1438
Character Count: 9075

Document Content:

Ross; or in each case to such other address as the person to be notified may have requested in writing. Any party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. 12. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in Section 7. Nothing in this Agreement is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or claim under or in respect of this Agreement or any provision herein contained. The term “successors and assigns” as herein used shall not include any purchaser, as such purchaser, of any of the Shares from any Underwriters.

13. Absence
of Fiduciary Relationship. The Company acknowledges and agrees that: (a) each Underwriter has been
retained solely to act as underwriter in connection with the sale of the Shares and that no fiduciary, advisory or agency relationship
between the Company and any Underwriter has been created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether the Underwriter has advised or is advising the Company on other matters; (b) the price and other terms of the Shares set forth
in this Agreement were established by the Company following discussions and arms-length negotiations with the Underwriters and the Company
is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated
by this Agreement; (c) it has been advised that the Underwriters and their affiliates are engaged in a broad range of transactions that
may involve interests that differ from those of the Company and that no Underwriter has any obligation to disclose such interest and
transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and (d) it has been advised that each Underwriter
is acting, in respect of the transactions contemplated by this Agreement, solely for the benefit of such Underwriter, and not on behalf
of the Company.

14. Amendments
and Waivers. No supplement, modification or waiver of this Agreement shall be binding unless executed
in writing by the party to be bound thereby. The failure of a party to exercise any right or remedy shall not be deemed or constitute
a waiver of such right or remedy in the future. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute
a waiver of any other provision hereof (regardless of whether similar), nor shall any such waiver be deemed or constitute a continuing
waiver unless otherwise expressly provided.

15. Partial
Unenforceability. The invalidity or unenforceability of any section, paragraph, clause or provision
of this Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision.

16. Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State
of New York.

17. Submission
to Jurisdiction. The Company irrevocably (a) submits to the jurisdiction of the Supreme Court of
the State of New York, Borough of Manhattan or the United States District Court for the Southern District of New York for the purpose
of any suit, action, or other proceeding arising out of this Agreement, or any of the agreements or transactions contemplated by this
Agreement, the Registration Statement, the Time of Sale Disclosure Package, any Prospectus and the Final Prospectus (each a “Proceeding”),
(b) agrees that all claims in respect of any Proceeding may be heard and determined in any such court, (c) waives, to the fullest extent
permitted by law, any immunity from jurisdiction of any such court or from any legal process therein, (d) agrees not to commence any
Proceeding other than in such courts, and (e) waives, to the fullest extent permitted by law, any claim that such Proceeding is brought
in an inconvenient forum. THE COMPANY (ON BEHALF OF ITSELF AND, TO THE FULLEST EXTENT PERMITTED BY LAW, ON BEHALF OF ITS EQUITY HOLDERS
AND CREDITORS) HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION
WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT, THE TIME OF SALE DISCLOSURE PACKAGE,
ANY PROSPECTUS AND THE FINAL PROSPECTUS.

18. Counterparts.
This Agreement may be executed and delivered (including by facsimile transmission or electronic
mail) in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be
an original and all such counterparts shall together constitute one and the same instrument.

[Signature
Page Follows]

Please
sign and return to the Company the enclosed duplicates of this letter whereupon this letter will become a binding agreement between the
Company and the several Underwriters in accordance with its terms.

Very truly
yours,

SYNERGY
CHC CORP.

Name:

Title:

Confirmed
as of the date first above-mentioned

the Representative of the several Underwriters

ROTH
CAPITAL PARTNERS, LLC

Name:	Aaron M. Gurewitz

Title:	Head of Equity Capital Markets

[Signature page to Underwriting Agreement]

SCHEDULE

Name Number of Firm Shares to be Purchased Number of Option Shares to be Purchased

Roth Capital Partners, LLC [●] [●]

Total [●] [●]

SCHEDULE

Final
Term Sheet

Issuer:	Synergy
CHC Corp. (the “Company”)

Symbol:	SNYR

Securities:	[●] shares of
common stock, par value $0.00001 per share (the “Common Stock”), of the Company.

Over-allotment option:	Up to an additional
[●] shares of Common Stock at a price of $[●] per share

Public offering price:	$[●] per share
of Common Stock

Underwriting discount:	$[●] per share
of Common Stock

Expected net proceeds:	Approximately $[●]
million ($[●] if the overallotment option is exercised in full) (after deducting the underwriting discount and estimated offering
expenses payable by the Company).

Trade date:	[●] ,

Settlement date:	[●] ,

Underwriters:	Roth
Capital Partners, LLC

SCHEDULE

Free
Writing Prospectus

None.

SCHEDULE

Written
Testing-the-Waters Communications

SCHEDULE

List
of officers, directors and stockholders executing lock-up agreements

EXHIBIT

Form
of Lock-Up Agreement

Roth
Capital Partners, LLC

San Clemente Drive

Newport
Beach, CA 92660

Ladies
and Gentlemen:

The
undersigned understands that you, as the representative (the “Representative”) of the several underwriters named therein,
propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Synergy CHC Corp., a Nevada corporation
(the “Company”), relating to a proposed offering of securities of the Company (the “Offering”) including shares
of the Common Stock, par value $0.00001 per share (the “Common Stock”). Capitalized terms used herein and not otherwise defined
shall have the meanings set forth in the Underwriting Agreement.

consideration of the foregoing, and in order to induce you to participate the Offering, and for other good and valuable consideration
receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representative
(which consent may be withheld in its sole discretion), the undersigned will not, during the period (the “Lock-Up Period”)
beginning on the date hereof and ending on the date 180 days after the date of the final prospectus relating to the Offering (the “Final
Prospectus”), (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly
or indirectly, or file (or participate in the filing of) a registration statement with the Securities and Exchange Commission in respect
of, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock (including
without limitation, shares of Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules
and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant),
(2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the
shares of, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of shares of Common Stock or
such other securities, in cash or otherwise, (3) make any demand for or exercise any right with respect to, the registration of any shares
of Common Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock, or (4) publicly announce
an intention to effect any transaction specific in clause (1), (2) or (3) above.